Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 18/20 | 0.72 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704137 | 0.90 | DHFR (0.73) | DHFRCHRNA10CHRNA9 | |
| SCHEMBL20804429 | 0.84 | DHFR (1.00) | DHFR | |
| SCHEMBL6700402 | 0.81 | DHFR (0.68) | DHFR | |
| SCHEMBL6703945 | 0.80 | DHFR (0.74) | DHFR | |
| SCHEMBL6697987 | 0.77 | DHFR (0.65) | DHFR | |
| SCHEMBL10650967 | 0.75 | DHFR (0.63) | DHFR | |
| SCHEMBL10650874 | 0.75 | DHFR (0.52) | DHFRCHRNA10CHRNA9 | |
| SCHEMBL20804430 | 0.74 | DHFR (1.00) | DHFR | |
| SCHEMBL20734782 | 0.73 | DHFR (1.00) | DHFR | |
| SCHEMBL11004401 | 0.72 | DHFR (0.73) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | BERRY DAVID ALLEN (US) | 2004-01-08 | — | — | US | claimed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | claimed |
| EP-0103464-B1 | DIAMINOPYRIMIDINES AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-11-17 | — | — | EP | claimed |
| US-4532240-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1985-07-30 | — | — | US | claimed |
| EP-0103464-A2 | Diaminopyrimidines and their production | WARNER-LAMBERT COMPANY (US) | 1984-03-21 | — | — | EP | claimed |
| US-11530198-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200407345-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | TURING PHARMACEUTICALS LLC | 2020-12-31 | — | — | US | disclosed |
| US-10774073-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC | 2020-08-27 | — | — | US | disclosed |
| US-20190077794-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | Vyera Pharmaceuticals, LLC (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2019032458-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | BERRY DAVID ALLEN (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0103464-B1 | DIAMINOPYRIMIDINES AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-11-17 | — | — | EP | disclosed |
| US-4532240-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
| EP-0103464-A2 | Diaminopyrimidines and their production | WARNER-LAMBERT COMPANY (US) | 1984-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | ABCB1, ABCC1, DPYD | DHFR 81/4885CHRNA10 4817/4885CHRNA9 4743/4885 |
| US-20190077794-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | DHFR, DHODH, QDPR | DHFR 1/4885CHRNA10 4852/4885CHRNA9 4815/4885 |
| US-20200407345-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | DHFR, DHODH, QDPR | DHFR 1/4885CHRNA10 4852/4885CHRNA9 4815/4885 |
| US-11530198-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | DHFR 1/4885CHRNA10 4852/4885CHRNA9 4815/4885 |
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | DHFR, DHODH, FPGS | DHFR 1/4885CHRNA10 4831/4885CHRNA9 4817/4885 |
| US-10774073-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | DHFR 1/4885CHRNA10 4852/4885CHRNA9 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.